2020
Influenza vaccine effectiveness and disease burden in children and adolescents with sickle cell disease: 2012‐2017
Kao CM, Lai K, McAteer JM, Elmontser M, Quincer EM, Yee MEM, Tippet A, Jerris RC, Lane PA, Anderson EJ, Bakshi N, Yildirim I. Influenza vaccine effectiveness and disease burden in children and adolescents with sickle cell disease: 2012‐2017. Pediatric Blood & Cancer 2020, 67: e28358. PMID: 32469138, PMCID: PMC8221251, DOI: 10.1002/pbc.28358.Peer-Reviewed Original ResearchConceptsInfluenza vaccine effectivenessSickle cell diseaseVaccine effectivenessYears of ageInfluenza infectionOdds ratioCell diseaseLaboratory-confirmed influenza infectionSeasonal influenza vaccine effectivenessTest-negative case-control study designAdjusted vaccine effectivenessAdjusted VE estimatesInfluenza-positive casesOverall vaccine effectivenessAcute chest syndromeBurden of influenzaPatients 6 monthsMulticenter prospective studyTest-negative controlsAnnual influenza vaccineCase-control study designConfidence intervalsLogistic regression modelsChest syndromeInfluenza season
2018
The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis
Balsells E, Dagan R, Yildirim I, Gounder PP, Steens A, Muñoz-Almagro C, Mameli C, Kandasamy R, Lavi N, Daprai L, van der Ende A, Trzciński K, Nzenze SA, Meiring S, Foster D, Bulkow LR, Rudolph K, Valero-Rello A, Ducker S, Vestrheim DF, von Gottberg A, Pelton SI, Zuccotti G, Pollard AJ, Sanders EAM, Campbell H, Madhi SA, Nair H, Kyaw MH. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis. Journal Of Infection 2018, 77: 368-378. PMID: 29964140, DOI: 10.1016/j.jinf.2018.06.004.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseInvasive disease potentialPneumococcal conjugate vaccineNon-vaccine typesPCV introductionPneumococcal diseaseClinical syndromePneumococcal serotypesSurveillance of IPDDisease potentialSystematic reviewCurrent pneumococcal conjugate vaccinesYears of ageRandom-effects modelConjugate vaccineRoutine immunisationDisease presentationFuture vaccinesStreptococcus pneumoniaeSerotype 1SerotypesSyndromeCarriageChildrenVaccine
2007
Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005
Ceyhan M, Yildirim I, Balmer P, Riley C, Laher G, Andrews N, Borrow R, Kurt N, Turgut M, Aydogan A, Ecevit C, Uysal G, Schultze V. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005. Vaccine 2007, 25: 7233-7237. PMID: 17707957, DOI: 10.1016/j.vaccine.2007.07.019.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overAntibodies, BacterialChildChild, PreschoolFemaleHumansImmunoglobulin GInfantInfant, NewbornMaleMeningococcal InfectionsMicrobial ViabilityMiddle AgedNeisseria meningitidis, Serogroup ANeisseria meningitidis, Serogroup CNeisseria meningitidis, Serogroup W-135Neisseria meningitidis, Serogroup YSeroepidemiologic StudiesTurkeyConceptsSerum bactericidal antibodySerogroups ASerogroup CIgG concentrationsMeningococcal serogroup C diseaseSerum bactericidal antibody activityTurkish populationMeningococcal serogroup CMeningococcal vaccination programsSerogroup C diseaseAge-specific seroprevalenceSpecific IgG concentrationsRates of susceptibilityBactericidal antibody activityBaseline seroprevalenceSBA titersAntibody levelsProtective antibodiesIgG antibodiesVaccination programBactericidal antibodiesHealth centersC diseaseStudy populationC meningococci